Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), has been strongly recommended by the 2024 American Diabetes Association Standards of Care in Diabetes for type 2 diabetes (T2D) treatment due to its efficacy in lowering blood glucose levels and promoting significant weight reduction [1]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.